Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma

• Published in: Cancers Vol. 15; no. 16; p. 4034
• Main Authors: Wu, Jerry T., Cheuk, Adam, Isanogle, Kristine, Robinson, Christina, Zhang, Xiaohu, Ceribelli, Michele, Beck, Erin, Shinn, Paul, Klumpp-Thomas, Carleen, Wilson, Kelli M., McKnight, Crystal, Itkin, Zina, Sotome, Hiroshi, Hirai, Hiroshi, Calleja, Elizabeth, Wacheck, Volker, Gouker, Brad, Peer, Cody J., Corvalan, Natalia, Milewski, David, Kim, Yong Y., Figg, William D., Edmondson, Elijah F., Thomas, Craig J., Difilippantonio, Simone, Wei, Jun S., Khan, Javed
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 09.08.2023; MDPI
• Subjects: Animal models; Antibodies; Biological products; Biotechnology industry; Cancer; Cell fusion; Chemotherapy; Clinical trials; Drug dosages; FDA approval; Fibroblast growth factor receptor 4; Fibroblast growth factor receptors; Fibroblasts; FOXO1 protein; Irinotecan; Kinases; Laboratory animals; Leukemia; Lymphocytes T; Medical research; Metastases; Pax3 protein; Pediatrics; Penicillin; Pharmaceutical industry; Phosphorylation; Protein-tyrosine kinase receptors; Proteins; R&D; Research & development; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma; T cells; Toxicity; Tumors; Tyrosine; Vincristine; Xenografts; United States; Japan; United Kingdom > UK; United States > US; FGFR inhibitor; FGFR4; rhabdomyosarcoma; futibatinib; pediatric cancer

Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma. Despite decades of clinical trials, the overall survival rate for patients with relapsed and metastatic disease remains below 30%, underscoring the need for novel treatments. FGFR4, a receptor tyrosine kinase that is overexpres...